肠道微生物群与阿尔茨海默病之间的相互作用:同一样本的重新分析
Lu Wang1, Xuhan Zuo2, Mengyan Xu1
1School of Public Health, Hainan Medical University, Haikou Hainan, China.
Journal of Alzheimer's disease : JAD
|September 4, 2025
概括
阿尔茨海默病 (AD) 显著改变了肠道微生物群的组成, 这项研究确定了潜在的阿尔茨海默病诊断的关键微生物变化和敏感年龄组.
科学领域:
- 微生物组研究
- 神经退行性疾病研究
- 肠-大脑轴研究
背景情况:
- 阿尔茨海默病 (AD) 是一种影响认知的神经退行性疾病.
- 人们越来越认识到肠道微生物在阿尔茨海默氏症的发病过程中的作用.
- 了解阿尔茨海默病中的微生物变化对于诊断进步至关重要.
研究的目的:
- 在阿尔茨海默病 (AD) 中识别特定的肠道微生物群变化.
- 分析年龄和性别对阿尔茨海默病相关微生物变化的影响.
- 发现新的肠道微生物组合用于阿尔茨海默病诊断.
主要方法:
- 从五项研究中获取和选了86个肠道微生物样本.
- 在98个物种的属级别分析了微生物的丰富性.
- 使用在线数据库 (GMrepo) 来获取数据.
主要成果:
- 在阿尔茨海默病患者中丰富了Clostridium,Ruminococcus,Roseburia和Faecalibacterium.
- 在肠道微生物群的均性和组成中确诊AD诱导的变化.
- 特定的敏感年龄组和特定性别的细菌物种对抗阿尔茨海默病的检测有意义.
结论:
- 发现肠道微生物群与阿尔茨海默病 (AD) 之间存在显著的关联.
- 特定的细菌物种显示为阿尔茨海默病的诊断生物标志物.
- 进一步的研究应该集中在关键细菌和基因上, 以确定因果关系.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


